Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C20H25FN4O |
| Molecular Weight | 356.4371 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CCN1CCN(CC1)C2=CC=C(F)C=C2)NC(=O)C3=CN=CC=C3
InChI
InChIKey=RSKQGBFMNPDPLR-UHFFFAOYSA-N
InChI=1S/C20H25FN4O/c1-16(23-20(26)17-3-2-9-22-15-17)8-10-24-11-13-25(14-12-24)19-6-4-18(21)5-7-19/h2-7,9,15-16H,8,10-14H2,1H3,(H,23,26)
| Molecular Formula | C20H25FN4O |
| Molecular Weight | 356.4371 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Niaprazine is a potent and selective antagonist of 5-HT2A and alpha-1 adrenergic receptors. It was used for the treatment of sleep disturbances in children and was investigated for the treatment of sleep disorders in patients with attention-deficit hyperactivity disorder and autistic disorder.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:18:21 GMT 2023
by
admin
on
Sat Dec 16 11:18:21 GMT 2023
|
| Record UNII |
1346Q758L9
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
119306-37-5
Created by
admin on Sat Dec 16 11:18:21 GMT 2023 , Edited by admin on Sat Dec 16 11:18:21 GMT 2023
|
PRIMARY | |||
|
1346Q758L9
Created by
admin on Sat Dec 16 11:18:21 GMT 2023 , Edited by admin on Sat Dec 16 11:18:21 GMT 2023
|
PRIMARY | |||
|
71919
Created by
admin on Sat Dec 16 11:18:21 GMT 2023 , Edited by admin on Sat Dec 16 11:18:21 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
